Bone metastases, whether osteolytic or osteoblastic in nature, typically spread to the spine, pelvis, skull, and long bones. By the time skeletal-related events start to manifest – be it pathological fractures, spinal compression, hypercalcemia or more – patient outcomes are already grim: to this day, bone metastases still lack a cure.The urgency for novel bone and orthopedic models has never been greater. With cancers such as melanoma, breast cancer, and colon cancer frequently metastasizing to the bones and drastically reducing survival rates, innovative treatment strategies are imperative. Over 100,000 cases of bone metastasis are diagnosed annually, underscoring the critical need for cutting-edge research and accelerated therapeutic development.At PharmaLegacy, our team of experts is relentless in its efforts to help you better understand bone metastasis, and ultimately, put a stop to it. With your pipelines and our decades of expertise, let’s stop metastases in their tracks.